<DOC>
	<DOCNO>NCT01931150</DOCNO>
	<brief_summary>The purpose study see investigator prevent reduce severity Cetuximab-related acne rash . Two different topical agent apply skin . One topical agent dapsone gel skin moisturizer . Dapsone gel FDA approve medication apply face . It commonly use treat acne . Skin moisturizers recommend patient receive Cetuximab treatment . In addition topical agent give pill take day . This pill already show help fight rash Cetuximab .</brief_summary>
	<brief_title>Study Prophylactic Topical Dapsone 5 % Gel Versus Moisturizer Cetuximab-induced Papulopustular ( Acneiform ) Rash Patients With mCRC HNSCC Without Previous Concurrent RT</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients 18 year old underlying diagnosis metastatic colorectal cancer head neck squamous cell carcinoma include newly diagnose patient Patients must provide write informed consent participate study Anticipated initiation cetuximab treatment without additional chemotherapy . Able selfadminister topical intervention provide another person apply topical intervention Females childbearing potential pregnant nursing Patients allergy , hypersensitivity contraindication dapsone , sulfa antibiotic , excipients dapsone gel product Patients preexist dermatologic condition affect face chest would impair assessment papulopustular rash include dense and/or long facial hair ( per investigator discretion ) Patients currently use prescription and/or overthecounter topical medication face and/or chest unwilling discontinue use trial intervention period ( day 0 ± 2 day day 28 ± 2 day ) Previous concurrent radiation therapy head , neck , chest ( i.e . application site ) Previous therapy cetuximab within 6 month consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Topical Dapsone 5 % Gel</keyword>
	<keyword>Moisturizer</keyword>
	<keyword>rash</keyword>
	<keyword>13-012</keyword>
</DOC>